Search

Home > GRACEcast Lung Cancer Video > Is there a new, promising option for people with the most common mutation seen in lung cancer?
Podcast: GRACEcast Lung Cancer Video
Episode:

Is there a new, promising option for people with the most common mutation seen in lung cancer?
Category: Science & Medicine
Duration: 00:05:58
Publish Date: 2013-01-26 22:12:00
Description:

Dr. Jack West reviews the encouraging results with selumetinib, a MEK inhibitor, in combination with chemotherapy for patients with advanced NSCLC and a KRAS mutation, the most common molecular marker seen in lung cancer. 
Total Play: 0